Chang, Y.-I.Y.-I.ChangCHII-SHEN YANG2018-09-102018-09-102014http://www.scopus.com/inward/record.url?eid=2-s2.0-84904070206&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/3843195hmc; Chronic myelomonocytic leukaemia; Oncogenic RAS; TET2; Whole exome sequencing[SDGs]SDG35 hydroxymethylcytosine; dioxygenase; tet methylcytosine dioxygenase 2; transcription factor EZH2; unclassified drug; adult; aged; allele; animal experiment; animal model; article; ASXL1 gene; cancer prognosis; cell nucleus; cellular distribution; chronic myelomonocytic leukemia; clinical article; controlled study; cytoplasm; Ezh2 gene; female; gene; gene mutation; HEK293 cell line; human; human cell; leukocyte count; male; middle aged; missense mutation; monocyte; mouse; NCSTN gene; nonhuman; oncogene K ras; oncogene N ras; point mutation; priority journal; splenomegaly; survival rate; tet methylcytosine dioxygenase 2 gene; 5hmc; chronic myelomonocytic leukaemia; oncogenic RAS; TET2; whole exome sequencing; Alleles; DNA Mutational Analysis; DNA-Binding Proteins; Epistasis, Genetic; GTP Phosphohydrolases; Humans; Leukemia; Membrane Proteins; Mutation; Prognosis; Proto-Oncogene Proteinsjournal article10.1111/bjh.12871